Supplementary table 5. The league table for SAE estimates interventions according to their relative effects in second part network analysis.

|  |  |  |
| --- | --- | --- |
| Atezolizumab(47.2%)# |  |  |
| -0.22 (-0.49,0.05) | ICC (2.8%) |  |
| **1.41 (0.91,1.90)##** | **1.63 (1.21,2.04)** | Pembrolizumab (100%) |

#: The SUCRA probabilities are performed in brackets.

##: Bold font means significant different.

Abbreviations: ICC: Investigator’s Choice Chemotherapy; SAE: Severe adverse effect.